Merck: European Commission Approves TEPMETKO (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

TEPMETKO is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping,

Related Keywords

United States ,China ,Japan ,Canada ,Netherlands ,Egbert Smit ,Anne Marie Baird ,Andrew Paterson ,European Commission ,Drug Administration ,Serono ,Netherlands Cancer Institute ,European Economic Area ,Professor Egbert Smit ,Netherlands Cancer ,New England Journal ,Lung Cancer ,Chief Marketing Officer ,Product Characteristics ,Englj Med ,Accessed February ,Merck ,European ,Commission ,Pproves ,Epmetko ,Tepotinib ,Patients ,Dvanced ,Nsclc ,Etex14 ,Skipping ,Alterations ,